In swine production, tetracycline hydrochloride is dispensed through drinking water systems as a soluble powder whose stock concentration must be matched to the dilution ratio of the proportioner pump. A target final drinking water concentration of 0.8 g/L at a 1:128 proportioner setting requires 102.4 g/L stock solution, calculated as Cstock = Cfinal × dilution factor. Release testing for such powders falls under USP <905> and USP <731> for dosage-unit uniformity and loss on drying, with a typical upper moisture acceptance limit of 2.0% w/w. Assay is performed by high-performance liquid chromatography according to ISO 13906:2008, and microbiological quality is assessed by USP <61> and USP <62>. Manufacturing uses a double-ribbon blender with a fill ratio of 50–70% of gross volume, jacket temperature maintained between 15°C and 25°C, and relative humidity below 30% RH to prevent caking. The API is pre-milled to a D₉₀ below 150 µm, then geometric dilution with dextrose monohydrate or lactose is performed over three stages of 10, 15, and 20 minutes. On production lines, the most frequent failure occurs when hard water with calcium hardness above 150 mg/L CaCO₃ enters the medicator: tetracycline chelates divalent cations, producing an insoluble precipitate on the in-line strainer and reducing delivered dose by as much as 25% if the stock solution is not acidified to pH 3.0–4.0 with citric acid or hydrochloric acid before mixing. Finished formats include 100 g and 500 g laminated aluminium sachets, 1 kg bulk jars for veterinary hospital dispensing, and liquid concentrates prepared immediately before use for proportioner systems. In the United States, the product is classified as a prescription veterinary drug under 21 CFR Part 520 and is manufactured under 21 CFR 211; in the European Union, national authorisations under Directive 2001/82/EC as replaced by Regulation 2019/6 govern the same water-borne application.

Poultry In-Feed Granulation: Shear, Moisture, and Premix Homogeneity

Medicated feed application in broiler and layer flocks is a different process from water medication because the tetracycline hydrochloride must survive steam conditioning and pelleting without excessive epimerization. The regulatory framework for in-feed use includes EU Regulation 2019/4 for medicated feed manufacture and, in the United States, the Veterinary Feed Directive provisions of 21 CFR Part 558 and the medicated feed CGMP rules in 21 CFR Part 225. Inclusion rate is not fixed as a simple percentage; it is derived from the prescribed dose of 22 mg/kg body weight/day divided by expected daily feed intake. For a 1.8 kg broiler consuming 110 g/day, the calculated complete feed concentration is 360 mg/kg. Commercial premixes are therefore commonly diluted with calcium carbonate to 1.0–10.0% w/w tetracycline hydrochloride before final mixing at 200–400 g per tonne of complete feed for the prescribed therapeutic window, with a withdrawal period as stated on the approved label. The manufacturing process begins with a carrier pre-mix in a horizontal ribbon mixer operating at 12–15 rpm; the API is pre-blended with a portion of carrier for 10 minutes before addition to the full charge. After 20 minutes of final mixing, batch release assay requires a coefficient of variation below 5.0% across ten sampling points. If the powder is subsequently pelleted through a ring die at 80–85°C conditioning temperature, the tetracycline HCl loss to epimerization should be quantified by ISO 13906:2008; adding molasses above 2.0% w/w increases the moisture of the pre-pellet meal beyond 15% and accelerates the formation of epitetracycline at the die surface. The final medicated articles are granular premixes in 20 kg multi-wall bags, pelleted feeds, and crumbles used for flock-level treatment under a veterinary directive.

What Limits Tetracycline Hydrochloride Solubility in Injectable Solutions?

Because the free base precipitates above pH 4.0, injectable formulation work is confined to a narrow window in which the hydrochloride salt remains dissolved and the API does not degrade excessively. The hydrochloride salt dissolves freely in aqueous media at pH 2.0–3.0, but raising the pH above 4.0 reduces solubility of the free base and causes precipitation during filtration. Aqueous veterinary injectable products are therefore developed at 50–100 mg/mL tetracycline hydrochloride; concentrations above 100 mg/mL generally require non-aqueous vehicles such as propylene glycol or glycofurol, and published scale-up data above 150 mg/mL are limited. Sterile production is governed by EU GMP Annex 1 and 21 CFR 211, with release testing per USP <71>, USP <788>, USP <790>, USP <791>, and ICH Q3D for elemental impurities. The process uses deoxygenated Water for Injection chilled to 8–15°C to slow oxidative degradation, with nitrogen overlay in the mixing vessel. The API is dissolved under high-shear agitation, pH is adjusted with hydrochloric acid, and the solution is passed through a 0.22 µm sterilising-grade membrane. Terminal steam sterilisation at 121°C for 15 minutes is not used for tetracycline HCl because epimerization under moist heat can exceed 10%; aseptic filtration and aseptic filling are standard instead. On filling lines, filter capacity can drop by more than 40% if the solution temperature falls below 8°C, because increased viscosity and early crystallisation foul the membrane pores. Incompatibility with calcium-containing diluents must be labelled: intravenous administration into lactated Ringer’s solution produces visible chelation precipitates. Finished container types are 100 mL, 250 mL, and 500 mL multidose vials for intramuscular, subcutaneous, and diluted intravenous administration in cattle and sheep.

For companion animal veterinary practice, tablet and capsule dosage forms containing tetracycline hydrochloride are manufactured by wet granulation rather than direct compression when the API fraction exceeds 40% w/w, because micronized tetracycline HCl exhibits poor flow and high die-wall adhesion. The dose is presented as 250 mg and 500 mg tablets or capsules for dogs, with drug loading between 35% and 60% w/w and a typical excipient system of microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, povidone, and magnesium stearate. Granulation uses water or an aqueous povidone solution in a high-shear granulator, followed by wet milling through a 1.0 mm screen and fluid-bed drying at an inlet temperature not exceeding 60°C; higher drying temperatures accelerate the formation of anhydrotetracycline, an impurity controlled by the tetracycline hydrochloride USP monograph. Tablets are compressed to hardness 8–12 kp, and disintegration is assessed by USP <701> with a limit of not more than 15 minutes in 0.1 M HCl. Dissolution testing follows USP <711> using 0.01 M HCl, with product-specific Q values submitted in the registration file. Capsule products are filled on an automatic capsule machine with relative humidity below 35% RH to prevent shell softening and API hydrolysis. Manufacturing and release fall under 21 CFR 211 in the United States and USP <905> for uniformity of dosage units; the corresponding EU national authorisations apply Directive 2001/82/EC as amended. The finished goods are packaged in blister strips or HDPE bottles of 100 and 500 count, intended for oral administration to dogs and cats under veterinary prescription.

When Tetracycline Ophthalmic Ointments Are Compounded Under Aseptic Conditions

Before an ophthalmic ointment batch can be released, the anhydrous base must be sterilized separately from the thermolabile tetracycline hydrochloride. The API is formulated at 1% w/w, equivalent to 10 mg/g, in an anhydrous ointment base of white petrolatum, mineral oil, and lanolin. Micronization to a D₉₀ below 50 µm is required to prevent corneal abrasion and to satisfy the metal-particle and insoluble-ingredient limits of USP <771>. Unlike nonsterile powders, the ointment requires aseptic processing because the API cannot be added before dry-heat sterilisation of the base. The base is melted at 70°C, passed through a 150 µm screen, and sterilised by dry heat at 150°C for 2 hours; the API is separately rendered sterile by gamma irradiation and then incorporated aseptically into the cooled base at 40–45°C using a rotor-stator homogeniser inside an ISO 5 laminar flow workstation. Sterility assurance is governed by EU GMP Annex 1 and 21 CFR 211, with release testing per USP <71>, USP <51>, and USP <771>. A process conflict emerges from residual moisture in the base: if water content exceeds 0.1% w/w, tetracycline hydrochloride hydrolyses over storage and the ointment darkens; therefore each base lot must be tested for loss on drying before aseptic incorporation. On production equipment, stainless steel homogeniser wear can introduce metal particles that fail USP <771>, so rotor-stator clearances are monitored after each batch. The terminal container type is the 3.5 g or 5 g collapsible aluminium tube with an ophthalmic tip, labelled for application to the conjunctival sac in dogs, cats, and horses.

Ruminant Oral Powders and the Milk Replacer Incompatibility Risk

In calf and lamb oral powders, the central formulation conflict is the chelation of tetracycline hydrochloride by calcium caseinate when the dose is suspended in milk replacer. The oral powder is compounded with a water-soluble carrier and an acidifier such as citric acid or malic acid to maintain the reconstituted liquid at pH 3.0–4.0; if the product is mixed with warm milk replacer at 45°C and calcium content above 150 mg/L CaCO₃ equivalents, flocculation appears within 5 minutes and the effective dose may fall below the label claim. Dosing is 10–20 mg/kg body weight twice daily for calves, administered by stomach tube or nipple feeder from a suspension prepared immediately before use at no more than 5 g/L when milk replacer is unavoidable. Manufacturing uses a twin-shell blender or ribbon mixer with a carrier of lactose monohydrate, colloidal silicon dioxide, and an organic acid blend; the powder is filled into aluminium foil sachets under 30% RH to prevent hydrolysis. Quality control includes ISO 13906:2008 assay, USP <731> loss on drying, and USP <905> fill weight variation. Regulatory control of this dosage form falls under 21 CFR Part 520 in the United States and under national veterinary medicines legislation in the EU pursuant to Directive 2001/82/EC, while medicated milk replacer prepared on farm may also trigger compliance with EU Regulation 2019/4 where the final mixture is classified as medicated feed. The terminal formats are 500 g and 1 kg foil sachets, 30 mL dial-a-dose oral paste syringes, and bulk oral powder packs for veterinary hospitals and calf ranches.